|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:class
|
analgesics
synthetic opioids
|
|
gptkbp:clinical_trial
|
gptkb:Alchem_Laboratories
gptkb:United_States
high
Phase II
Phase I
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:combatants
|
high affinity for mu-opioid receptor
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Alchem_Laboratories
|
|
gptkbp:duration
|
as needed
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:field_of_study
|
pharmacology
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:formulation
|
extended-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0700
|
|
gptkbp:indication
|
chronic pain
|
|
gptkbp:ingredients
|
C20 H25 N3 O2
|
|
gptkbp:interacts_with
|
CY P450 inhibitors
|
|
gptkbp:invention
|
gptkb:Alchem_Laboratories
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of pain
|
|
gptkbp:lifespan
|
4 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
planned
not yet marketed
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
chronic pain patients
|
|
gptkbp:receives_funding_from
|
government grants
|
|
gptkbp:regulatory_compliance
|
pending
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:safety_features
|
ongoing
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
nausea
constipation
respiratory depression
addiction potential
|
|
gptkbp:social_structure
|
complex organic structure
|
|
gptkbp:status
|
under investigation
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
opioid receptors
agonist
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
325.44 g/mol
|
|
gptkbp:year_created
|
gptkb:2020
|